Transcatheter aortic valve implantation (TAVI) has become the standard treatment for elderly patients with severe symptomatic aortic stenosis. While this has led to the development of new devices with different features, evidence from randomized studies on these new scaffolds is limited. The randomized SCOPE I study (Safety and Efficacy of the Symetis ACURATE Neo/TF Compared<a href="https://solaci.org/en/2023/07/24/scope-i-results-at-3-years-acurate-neo-vs-sapien-3/" title="Read more" >...</a>
At present, transcatheter aortic valve replacement (TAVR) has become increasingly common to treat severe symptomatic aortic stenosis, with the transfemoral approach being the most common access strategy, associated to better outcomes vs. other access sites. Even though vascular complication rates (VC) have dropped given increased operation experience and improved devices, such as the use of<a href="https://solaci.org/en/2023/06/27/vasc-observant-ii-substudy-impact-of-vascular-complications-after-tavr/" title="Read more" >...</a>
TLR associated factors in patients with calcified nodules. Patients with complex cardiomyopathies undergoing percutaneous coronary intervention are increasingly common, as is the case for calcified lesions and calcified nodules (CN). Procedure complexity not only involves planning, but also establishing patient prognosis, taking into consideration the fact that most target vessel events occur at long term<a href="https://solaci.org/en/2023/06/24/calcified-nodules-and-the-importance-of-oct-categorization-prior-pci/" title="Read more" >...</a>
Results of infrapopliteal territory revascularization in critical limb ischemia. Compared against the general population, patients suffering from critical lower limb ischemia (CLI) not only experience seriously limited quality of life, but also face a significant higher risk of death and amputation. Specifically, the optimal treatment for these patients remains uncertain. This uncertainty was sparked by<a href="https://solaci.org/en/2023/06/22/basil-2-revascularization-of-infra-popliteal-territory-in-patients-with-critical-lower-limb-ischemia/" title="Read more" >...</a>
Transcatheter aortic valve replacement (TAVR) in low-risk patients has been shown to be superior or noninferior in randomized studies, but the presence of valvular thrombosis, in its different forms, has not been well analyzed, nor is there much information on its impact on evolution. Researchers conducted an analysis of the LTR study that included 200<a href="https://solaci.org/en/2023/06/07/tavr-does-halt-affect-follow-up/" title="Read more" >...</a>
The ACURATE Neo2 valve is an evolution of the first-generation ACURATE Neo valve with a low rate of pacemaker implantation and a decrease in paravalvular leak, also compatible with the 14F introducer. This prospective study included patients with symptomatic severe aortic stenosis at high surgical risk who underwent ACURATE Neo2 valve implantation. The primary endpoint<a href="https://solaci.org/en/2023/05/23/europcr-2023-acurate-neo2-results-after-5-years/" title="Read more" >...</a>
Patients presenting aortic stenosis with cardiogenic shock are at extreme risk, with 70% mortality until the aortic obstruction is resolved, and taking into account they make poor transplant candidates. Safety and efficacy of TAVR in patients with cardiogenic shock remains unclear. The aim of this study was to assess events in patients undergoing TAVR with<a href="https://solaci.org/en/2023/05/17/europcr-2023-tavr-in-cardiogenic-shock/" title="Read more" >...</a>
Predictors of post PCI angina Among the complications of ischemic cardiomyopathy stenting, those called chronic, with significant functional and mental compromise, might affect patient quality of life. This can be observed in different scenarios, such as instent restenosis and post PCI angina. This kind of complications is associated with anxiety and depression at long term. <a href="https://solaci.org/en/2023/05/09/post-pci-angina-inevitable-or-avoidable/" title="Read more" >...</a>
Transcatheter aortic valve replacement has shown important benefits but one of its biggest challenges is showing its safety and efficacy at followup in low risk patients. At present we have 2-year data from the Evolute Low Risk, but the we lack information at longer followup. The study looked at 3-year followup of the Evolute Low<a href="https://solaci.org/en/2023/05/03/evolute-low-risk-at-3-years-promising-outcomes/" title="Read more" >...</a>
We are well aware of the benefits of TAVR in different scenarios, but the need for permanent pacemaker implantation (PPI) in self-expandable valves is between 15% and 30% according to different randomized and non-randomized studies. This is why the higher implantation strategy or cusp overlap (COT) was developed and, though it has been shown to<a href="https://solaci.org/en/2023/04/20/is-there-a-way-to-reduce-the-need-for-permanent-pacemaker-implantation-in-self-expanding-valves/" title="Read more" >...</a>